The elderly who are over 75 years old in Ciego de Ávila will receive preventive treatments with the drug Biomodulin T, leader of the Cuban pharmaceutical industry, to face the deadly outbreak of COVID-19 that the central province has registered.
The cytorestorative and immunomodulatory drug will be administered intravenously, at the rate of one dose every seven days, for six consecutive weeks, the local newspaper Invasor reported.
Ciego de Ávila has reported about 300 new contagions in September, which is why it has the island’s highest incidence rate of patients per 100,000 inhabitants.
The outbreak of COVID-19 in that province has cost the lives of 16 people so far this month, after adding three deaths this weekend, which is why the Cuban health authorities have taken extraordinary measures to control the expansion and severity of the wave of contagions.
The treatment with Biomodulin T is based voluntary for people over 75 years of age, although other younger adults showed up on the first day of application, according to the source.
Dr. Yurisán Espinosa, director of Science and Technological Innovation at the University of Medical Sciences, explained that “the Transfer Factor (HERBERTRANS), another Cuban product that fundamentally increases cellular immunity,” will be applied to the segment of people in the age range between 60 to 74 years.
Last week began the application of nasal interferon to health professionals, workers, patients and companions of the Antonio Luaces Iraola and Roberto Rodríguez hospitals, in Ciego and Morón, respectively.
The medicine will be gradually supplied to all workers in the health sector in Ciego de Ávila, Invasor said.
Cuban Minister of Public Health José Ángel Portal, along with a “select group of specialists and executives at the highest level,” are currently in that province to check, assess the epidemiological situation and compliance with the protocols.
According to the source, some 120 health professionals from various provinces joined the work in the main Ciego de Ávila medical institutions to help their colleagues in the treatment of COVID-19 patients.